Table 1

Baseline disease characteristics of 178 patients with axial spondyloarthritis from the GESPIC cohort included in the analysis

Parameter at baseline
Age, years (mean±SD)38.1±10.7
Male sex, n (%)89 (50)
HLA-B27 positives, n (%)135 (75.8)
Definite radiographic sacroiliitis according to the modified New York criteria, n (%)100 (56.2)
Duration of symptoms, years (mean±SD)4.3±2.8
BASDAI, points NRS (mean±SD)3.9±2.1
BASFI, points NRS (mean±SD)2.9±2.3
ASDAS (mean±SD)2.5±0.9
CRP, mg/L (mean±SD)10.0±15.7
Elevated CRP (>6 mg/L), n (%)76 (42.7)
Treatment, n (%)
 NSAIDs122 (68.5)
 NSAID intake score (mean±SD)33.4±27.6
 TNF-α inhibitors4 (2.2)
 DMARDs57 (32.0)
 Glucocorticoids12 (6.7)
mSASSS, points4.64±8.90
Syndesmophytes present, n (%)56 (31.5)
Current smoking, n (%)68 (38.2)
  • ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; DMARDs, disease-modifying anti-inflammatory drugs; GESPIC, GErman SPondyloarthritis Inception Cohort; HLA-B27, human leucocyte antigen B27; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NRS, numeric rating scale; NSAIDs, non-steroidal anti-inflammatory drugs; TNF-α, tumour necrosis factor α.